Filter Releases
 
Press Releases
Date Title and Summary View
Dec 21, 2014
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical ExperienceRadius Remains on Track for Completion of the Ongoing 6-Month ACTIVExtend Study and NDA Submission in the Second Half of 2015Radius' Investigati...
Dec 19, 2014
WALTHAM, Mass., Dec. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for its investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD) being developed for potential use in met...
Dec 15, 2014
As a result of the annual re-ranking of the NASDAQ Biotechnology Index, NASDAQ announced today that Radius Health shares will be added to the index effective before the market open on Monday, December 22, 2014. WALTHAM, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) will be added to the NASDAQ Biotechnology Index (Na...
Dec 11, 2014
WALTHAM, Mass., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it presented data from a Phase 1 clinical study on estrogen receptor engagement by the investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD), in a poster presentation at the 2014 San Antonio Breast Cancer Symposium (...
Nov 24, 2014
-- Multi-center, multi-national, double-blind, placebo-controlled trial in which postmenopausal women were randomized to receive 24-weeks of treatment with either daily subcutaneous injections of placebo, the investigational drug abaloparatide 20, 40 or 80-μg, or teriparatide 20-μg. A 24-week extension also was performed in a subset of su...
Nov 17, 2014
Company selected to present at Informa's Therapeutic Area Partnerships meeting at 1:30 pm ET on Thursday, November 20 in Boston WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its investigat...
Nov 17, 2014
WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that President and CEO, Robert Ward, is scheduled to present at the Jefferies Global London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on November 20 at the Waldorf Hilton in London.About Radius Health Radius is a science-driven bioph...
Nov 10, 2014
WALTHAM, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, reported its financial results for the third quar...
Nov 3, 2014
WALTHAM, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today the appointment of Dr. Willard H. Dere, to its Board of Directors. Dr. Dere was formerly at Amgen, where he led the development program of Prolia. "We are very pleased to welcome Dr. Willard Dere to the Radius Health Board," said President and CEO...
Oct 28, 2014
WALTHAM, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its Vice President, Business Development & Strategy, Geoffrey A. Swire, will present at the BIO-Europe Conference on Wednesday, November 5, 2014 at 12:45 p.m. Central European Time at the Portalhaus Messe Frankfurt, in Frankfurt, Germany. BI...
Oct 23, 2014
WALTHAM, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today it is a sponsor of The Cancer Support Community's symposium, "The Patient Voice: The First Year of the Cancer Experience Registry," in recognition of National Breast Cancer Awareness Month. Radius is pleased to help be a sponsor of this patient-focus...
Oct 21, 2014
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2014 financial results on Tuesday, November 11, 2014. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Tuesday, November 11, 2014 to disc...
Oct 2, 2014
WALTHAM, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, announced today that it has priced its public offeri...
Oct 1, 2014
WALTHAM, Mass., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commencing an underwritte...
Sep 25, 2014
Radius Health Summarizes Recent Presentations regarding its Investigational Drug Abaloparatide at the American Society for Bone and Mineral Research and for its Investigational Drug RAD1901 at the 4th Annual Brain Metastases Research and Emerging Therapy ConferenceInvestigational Drug Abaloparatide Currently in Phase 3 Clinical Development, Top Lin...
= add release to Briefcase